ASCO 2023 | LIBERATE: focused ultrasound to enhance liquid biopsies in glioblastoma

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health South Florida, Miami, FL, provides an overview of the LIBERATE trial (NCT05383872), which assessed the role of focused ultrasound to collect more circulating tumor DNA (ctDNA) for liquid biopsies from the brain in patients with glioblastoma. Liquid biopsies for glioblastoma are currently limited due to the blood brain barrier (BBB), and focused ultrasound will theoretically non-invasively disrupt the BBB to increase ctDNA in blood for liquid biopsy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.